Cost-effectiveness analysis of Vaborem in Carbapenem-resistant Enterobacterales (CRE) -Klebsiella pneumoniae infections in Italy

Cost-effectiveness analysis of Vaborem in Carbapenem-resistant Enterobacterales (CRE) -Klebsiella pneumoniae infections in Italy

Abstract Background Vaborem is a fixed dose combination of vaborbactam and meropenem with potent activity against target Carbapenem-resistant Enterobacterales (CRE) pathogens, optimally developed for Klebsiella pneumoniae carbapenemase (KPC). The study aims to evaluate the cost-effectiveness of Vabo...

Full description

Bibliographic Details
Main Authors: Francesco Saverio Mennini, Mario Gori, Ioanna Vlachaki, Francesca Fiorentino, Paola La Malfa, Duccio Urbinati, Massimo Andreoni
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Health Economics Review
Online Access:https://doi.org/10.1186/s13561-021-00341-z

Internet

https://doi.org/10.1186/s13561-021-00341-z

Similar Items